Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Maas, AI; Murray, G; Henney, H; Kassem, N; Legrand, V; Mangelus, M; Muizelaar, JP; Stocchetti, N; Knoller, N; Pharmos TBI investigators.
Efficacy and safety of dexanabinol in severe traumatic brain injury: results of a phase III randomised, placebo-controlled, clinical trial.
Lancet Neurol. 2006; 5(1): 38-45.
Doi: 10.1016/S1474-4422(05)70253-2
Web of Science
PubMed
FullText
FullText_MUG
- Study Group Mitglieder der Med Uni Graz:
- Tritthart Hans
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- BACKGROUND: Traumatic brain injury is a major cause of death and disability. We sought to assess the safety and efficacy of dexanabinol, a synthetic cannabinoid analogue devoid of psychotropic activity, in severe traumatic brain injury. METHODS: 861 patients with severe traumatic brain injury admitted to 86 specialist centres from 15 countries were included in a multi-centre, placebo-controlled, phase III trial. Patients were randomised to receive a single intravenous 150 mg dose of dexanabinol or placebo within 6 h of injury. The primary outcome was the extended Glasgow outcome scale assessed at 6 months, with the point of dichotomisation into unfavourable versus favourable outcome differentiated by baseline prognostic risk. Prespecified subgroup analyses were defined by injury severity, recruitment rate, and time to dosing. Secondary analysis included control of intracranial pressure and quality of life. Analysis were prespecified in the protocol and the statistical analysis plan. This study is registered with ClinicalTrials.gov, number NCT00129857. FINDINGS: 846 patients were included in the efficacy analysis. The extended Glasgow outcome scale at 6 months did not differ between groups; 215 (50%) patients in the dexanabinol group and 214 (51%) patients in the placebo group had an unfavourable outcome (odds ratio for a favourable response 1.04; 95% CI 0.79-1.36). Improvements in the control of intracranial pressure or quality of life were not recorded and subgroup analysis showed no indication of differential treatment effects. Dexanabinol was not associated with hepatic, renal, or cardiac toxic effects. INTERPRETATION: Dexanabinol is safe, but is not efficacious in the treatment of traumatic brain injury.
- Find related publications in this database (using NLM MeSH Indexing)
- Adolescent -
- Adult -
- Aged -
- Brain Injuries - drug therapy
- Chi-Square Distribution - drug therapy
- Confidence Intervals - drug therapy
- Dose-Response Relationship, Drug - drug therapy
- Double-Blind Method - drug therapy
- Female - drug therapy
- Follow-Up Studies - drug therapy
- Glasgow Coma Scale - statistics and numerical data
- Humans - statistics and numerical data
- Intracranial Pressure - drug effects
- Male - drug effects
- Middle Aged - drug effects
- Neuroprotective Agents - therapeutic use
- Odds Ratio - therapeutic use
- Quality of Life - therapeutic use
- Retrospective Studies - therapeutic use
- Tetrahydrocannabinol - analogs and derivatives
- Time Factors - analogs and derivatives
- Treatment Outcome - analogs and derivatives